NMR Experiment |
---|
Experiment | Type | Sample Contents | Solvent | Ionic Strength | pH | Pressure | Temperature (K) | Spectrometer |
---|
1 | 2D 1H-15N HSQC | 1.7 mM [U-100% 13C; U-100% 15N] SARS-CoV-2 nsp7, 10 mM MOPS, 150 mM sodium chloride, 2 mM DTT, 0.025 % sodium azide | 93% H2O/7% D2O | 150 mM | 7.0 | 1 atm | 298 | Varian VNMRS 600 |
2 | 3D HNCACB | 1.7 mM [U-100% 13C; U-100% 15N] SARS-CoV-2 nsp7, 10 mM MOPS, 150 mM sodium chloride, 2 mM DTT, 0.025 % sodium azide | 93% H2O/7% D2O | 150 mM | 7.0 | 1 atm | 298 | Varian VNMRS 600 |
3 | 3D CBCA(CO)NH | 1.7 mM [U-100% 13C; U-100% 15N] SARS-CoV-2 nsp7, 10 mM MOPS, 150 mM sodium chloride, 2 mM DTT, 0.025 % sodium azide | 93% H2O/7% D2O | 150 mM | 7.0 | 1 atm | 298 | Varian VNMRS 600 |
4 | 3D HNCO | 1.7 mM [U-100% 13C; U-100% 15N] SARS-CoV-2 nsp7, 10 mM MOPS, 150 mM sodium chloride, 2 mM DTT, 0.025 % sodium azide | 93% H2O/7% D2O | 150 mM | 7.0 | 1 atm | 298 | Varian VNMRS 600 |
5 | 3D HN(CA)CO | 1.7 mM [U-100% 13C; U-100% 15N] SARS-CoV-2 nsp7, 10 mM MOPS, 150 mM sodium chloride, 2 mM DTT, 0.025 % sodium azide | 93% H2O/7% D2O | 150 mM | 7.0 | 1 atm | 298 | Varian VNMRS 600 |
6 | 2D 1H-13C HSQC aliphatic | 1.7 mM [U-100% 13C; U-100% 15N] SARS-CoV-2 nsp7, 10 mM MOPS, 150 mM sodium chloride, 2 mM DTT, 0.025 % sodium azide | 93% H2O/7% D2O | 150 mM | 7.0 | 1 atm | 298 | Varian VNMRS 600 |
7 | 3D C(CO)NH | 1.7 mM [U-100% 13C; U-100% 15N] SARS-CoV-2 nsp7, 10 mM MOPS, 150 mM sodium chloride, 2 mM DTT, 0.025 % sodium azide | 93% H2O/7% D2O | 150 mM | 7.0 | 1 atm | 298 | Varian VNMRS 600 |
8 | 3D HBHA(CO)NH | 1.7 mM [U-100% 13C; U-100% 15N] SARS-CoV-2 nsp7, 10 mM MOPS, 150 mM sodium chloride, 2 mM DTT, 0.025 % sodium azide | 93% H2O/7% D2O | 150 mM | 7.0 | 1 atm | 298 | Varian VNMRS 600 |
9 | 3D H(CCO)NH | 1.7 mM [U-100% 13C; U-100% 15N] SARS-CoV-2 nsp7, 10 mM MOPS, 150 mM sodium chloride, 2 mM DTT, 0.025 % sodium azide | 93% H2O/7% D2O | 150 mM | 7.0 | 1 atm | 298 | Varian VNMRS 600 |
10 | 3D H(C)CH-TOCSY aliphatic | 1.7 mM [U-100% 13C; U-100% 15N] SARS-CoV-2 nsp7, 10 mM MOPS, 150 mM sodium chloride, 2 mM DTT, 0.025 % sodium azide | 93% H2O/7% D2O | 150 mM | 7.0 | 1 atm | 298 | Varian VNMRS 600 |
11 | 3D 1H-13C NOESY aliphatic | 1.7 mM [U-100% 13C; U-100% 15N] SARS-CoV-2 nsp7, 10 mM MOPS, 150 mM sodium chloride, 2 mM DTT, 0.025 % sodium azide | 93% H2O/7% D2O | 150 mM | 7.0 | 1 atm | 298 | Varian VNMRS 600 |
12 | 2D 1H-13C HSQC aromatic | 1.7 mM [U-100% 13C; U-100% 15N] SARS-CoV-2 nsp7, 10 mM MOPS, 150 mM sodium chloride, 2 mM DTT, 0.025 % sodium azide | 93% H2O/7% D2O | 150 mM | 7.0 | 1 atm | 298 | Bruker AVANCE III 600 |
13 | 3D (HB)CB(CGCD)HE | 1.7 mM [U-100% 13C; U-100% 15N] SARS-CoV-2 nsp7, 10 mM MOPS, 150 mM sodium chloride, 2 mM DTT, 0.025 % sodium azide | 93% H2O/7% D2O | 150 mM | 7.0 | 1 atm | 298 | Bruker AVANCE III 600 |
14 | 3D H(C)CH-TOCSY aromatic | 1.7 mM [U-100% 13C; U-100% 15N] SARS-CoV-2 nsp7, 10 mM MOPS, 150 mM sodium chloride, 2 mM DTT, 0.025 % sodium azide | 93% H2O/7% D2O | 150 mM | 7.0 | 1 atm | 298 | Bruker AVANCE III 600 |
15 | 3D 1H-13C NOESY aromatic | 1.7 mM [U-100% 13C; U-100% 15N] SARS-CoV-2 nsp7, 10 mM MOPS, 150 mM sodium chloride, 2 mM DTT, 0.025 % sodium azide | 93% H2O/7% D2O | 150 mM | 7.0 | 1 atm | 298 | Bruker AVANCE III 600 |